An interventional study of Cilostazol in Intermittent Claudication, sponsored by Roxane Laboratories. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Roxane Laboratories (part of Hikma Pharmaceuticals) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Intermittent Claudication with a site in United States — 14 open to participants now, 17 under way, 2 of them phase 3. Intermittent Claudication · United States.
Among the 119 studies in Intermittent Claudication with a site in United States, this one is the 74th largest by enrollment of the 104 interventional ones that give a count, is one of 7 that started in 2003, is one of 43 with no phase, and was the 28th registered.
309 studies on the registry are indexed under Intermittent Claudication; 46 are open to participants now.
Browse Intermittent Claudication studies →14 of the 119 studies in Intermittent Claudication with a site in United States are open now. Recruiting first, the newest first:
Cook Research Incorporated · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 50+
Northwestern University · Sites in United States
Ages 50+
University of Oklahoma · Sites in United States
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Intermittent Claudication studies recruiting now, 21 (64%) set no upper age limit and none (0%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 24 · Phase 3 13 · Phase 4 9
First in 1994; this study’s year is marked. 7 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 74 across 242 interventional studies indexed under Intermittent Claudication.
Median enrollment 73 across the 104 interventional studies, 195 across the 15 observational. Of the 87 that completed or were terminated, 30 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 119 have an industry lead sponsor. The 10 most frequent:
This study is registered under Roxane Laboratories, one of the names counted as Hikma Pharmaceuticals. Under that name alone:
Roxane Laboratories is the lead sponsor of 99 studies on the registry; none are open to participants now.
Hikma Pharmaceuticals has 2 studies filed under Intermittent Claudication — fewer than ten, so there is no comparison to draw.
7 of the studies in Intermittent Claudication with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT05145478Yale UniversityCRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions | 2026-12-31 |
| NCT02842424University of NebraskaRamipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis | 2027-06 |
| NCT06041880Penn State UniversityPassive Calf Stretching Therapy in Peripheral Artery Disease | 2027-06 |
| NCT06399809Northwestern UniversityFisetin to Reduce Senescence and Mobility Impairment in PAD | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 119 studies in Intermittent Claudication with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 100 mg, to PLETAL® Tablets, 100 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 3-treatment, 3-period, crossover design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bioequivalence
Time frame: Baseline, Two period, Seven day washout
The record gives a start of May 2003, a primary completion of May 2003 and a completion of May 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilostazol